Last reviewed · How we verify
Atorvastatin, Amlodipine, Perindopril
This is a fixed-dose combination of three cardiovascular agents that work together to lower cholesterol, reduce blood pressure, and improve heart function.
Atorvastatin, Amlodipine, and Perindopril are a combination of drugs developed by Charles University in the Czech Republic. Atorvastatin is a statin that lowers cholesterol, Amlodipine is a calcium channel blocker used to treat hypertension and angina, and Perindopril is an ACE inhibitor used for hypertension and heart failure. The combination is not approved by the FDA but is under investigation for potential synergistic effects in managing cardiovascular diseases. The safety profile of each drug is well-established individually, but the combination's safety and efficacy require further clinical trials. The commercial potential of this combination therapy is promising, especially in markets where cardiovascular diseases are prevalent.
At a glance
| Generic name | Atorvastatin, Amlodipine, Perindopril |
|---|---|
| Sponsor | Charles University, Czech Republic |
| Drug class | Fixed-dose combination: statin, calcium channel blocker, ACE inhibitor |
| Target | HMG-CoA reductase (atorvastatin); L-type calcium channels (amlodipine); Angiotensin-converting enzyme (perindopril) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Atorvastatin inhibits HMG-CoA reductase to reduce LDL cholesterol synthesis. Amlodipine is a calcium channel blocker that dilates blood vessels and reduces blood pressure. Perindopril is an ACE inhibitor that reduces angiotensin II-mediated vasoconstriction and lowers blood pressure. Together, they address multiple cardiovascular risk factors.
Approved indications
- Hypertension with dyslipidemia
- Cardiovascular disease prevention in patients requiring combination therapy
Common side effects
- Headache
- Peripheral edema
- Dizziness
- Muscle pain or myalgia
- Cough
- Fatigue
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: